VistaGen Therapeutics Inc. VTGN Archives

ThursdayJul 22, 2021 10:21 am

QualityStocksNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Strategic Board Appointment

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Maggie FitzPatrick to its board of directors. FitzPatrick replaces Dr. Brian J. Underdown, who recently retired from the board. “Maggie is a highly regarded public affairs strategist with extensive experience developing and executing multiple high impact customer-focused marketing communications initiatives for some of the world’s largest and most successful companies, including Johnson & Johnson and Cigna,” said Shawn Singh, CEO of VistaGen. “Her expertise in positioning companies…

FridayJul 09, 2021 10:19 am

QualityStocksNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in William Blair Biotech Focus Conference

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, will be part of this year’s online William Blair Biotech Focus Conference. VTGN management will participate in a panel discussion titled “Updates in Neuropsych.” Key executives will also be available for one-on-one meetings throughout the virtual conference, which will be held July 15. The panel discussion is slated to begin at 9 a.m. PT. In the announcement, VTGN noted that the panel…

WednesdayJul 07, 2021 1:11 pm

QualityStocksNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Key Board Appointment of Mary L. Rotunno

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Mary L. Rotunno, J.D. to its board of directors. “Mary brings to our team more than 30 years of leadership experience, which began with serving patients as a registered nurse and transitioned to serving clients in health care law, both allowing her to pursue her steadfast commitment to helping others and advancing the future of mental health and wellness,” said VistaGen CEO Shawn Singh.…

WednesdayJun 30, 2021 10:12 am

QualityStocksNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2021 Financial Results, Corporate Highlights

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has reported its financial results for fiscal year ended March 31, 2021; the company also provided a corporate update, noting that its PALISADE-1 phase 3 trial designed to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (“SAD”) is under way. The announcement also noted that the company is preparing to initiate several exploratory phase 2A clinical trials of…

FridayJun 25, 2021 11:06 am

QualityStocksNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Conference Call to Discuss 2021 FY Results, Provide Business Update

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will host a conference call to provide a business update and discuss financial and operating results for its fiscal year ended March 31, 2021. The call is scheduled to begin at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on Tuesday, June 29, 2021. VistaGen CEO Shawn Singh and other members of the company’s management team will host the call and provide an update…

ThursdayJun 17, 2021 10:28 am

QualityStocksNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Plans to Join Russell 2000 Index

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, will be added to the Russell 2000(R) Index effective Monday, June 28, 2021. The company will be added to the index at the conclusion of the 2021 Russell Indexes annual reconstitution. Investment managers and institutional investors often use the Russell U.S. Indexes, which are part of global index provider FTSE Russell, as a basis for index funds and as benchmarks for active…

WednesdayMay 26, 2021 12:10 pm

QualityStocksNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Initiation of PALISADE Phase 3 Study of PH94B in SAD

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, is beginning its PALISADE-1 phase 3 trial. The randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of VTGN’s PH94B (“PH94B”) for the treatment of anxiety in adults with Social Anxiety Disorder (“SAD”). In the announcement, the company noted there is no FDA-approved acute treatment for the disorder. The company plans to include some 200 randomized subjects in the study, which…

ThursdayMay 20, 2021 12:11 pm

QualityStocksNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Presentation Schedule for June Investor Conferences

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will present at two investor conferences slated to take place in June. These include scheduled presentations, as detailed in the update, at the Jefferies Virtual Healthcare Conference and the William Blair 41st Annual Virtual Growth Stock Conference. Interested parties should visit the sponsor’s conference website for more information regarding these events. To view the full press release, visit https://ibn.fm/WkY5l About VistaGen Therapeutics Inc. VistaGen is…

TuesdayMay 04, 2021 4:21 pm

QualityStocksNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Appoints Proven Pharmaceutical Exec as Chief Commercial Officer

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Ann Cunningham as its chief commercial officer. Cunningham, who has been and will continue serving on VTGN’s board of directors, has a proven pharmaceutical commercial track record of more than 25 years delivering sales, marketing and global life cycle product management expertise in roles across several health care markets, including neuropsychiatry and other CNS markets that VistaGen is pursuing. “Since joining our board, Ann’s…

TuesdayApr 27, 2021 2:04 pm

QualityStocksNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Board Appointment of Dr. Joanne Curley

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Joanne Curley, Ph.D. to its board of directors. VistaGen’s board will be comprised of seven directors following Dr. Curley’s appointment. “Joanne brings more than 25 years of pharmaceutical industry experience across numerous key operational and therapeutic areas,” said Shawn Singh, chief executive officer of VistaGen. “Her track record of propelling seven products from early development through regulatory approval is impressive and reflects her extensive…

Site Search

Company Search

Tag: VistaGen Therapeutics Inc. VTGN